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Abstract 
We aimed to investigate a novel and uncharacterised E3 ubiquitin ligase in skeletal muscle 
atrophy, recovery from atrophy/injury, anabolism and hypertrophy. We demonstrated an 
alternate gene expression profile for UBR5 versus well characterised E3-ligases, 
MuRF1/MAFbx, where after atrophy evoked by continuous-low-frequency electrical-
stimulation in rats, MuRF1/MAFbx were both elevated yet UBR5 was unchanged. 
Furthermore, after recovery of muscle mass post tetrodotoxin (TTX) induced-atrophy in rats, 
UBR5 was hypomethylated and increased at the gene expression level, while a suppression 
of MuRF1/MAFbx was observed. At the protein level, we also demonstrated a significant 
increase in UBR5 after recovery of muscle mass from hindlimb unloading in both adult and 
aged rats, and after recovery from atrophy evoked by nerve crush injury in mice. During 
anabolism and hypertrophy, UBR5 gene expression increased following acute loading in 
three-dimensional bioengineered mouse muscle in-vitro, and after chronic electrical-
stimulation-induced hypertrophy in rats in-vivo, without increases in MuRF1/MAFbx. 
Additionally, UBR5 protein abundance increased following functional overload-induced 
hypertrophy of the plantaris muscle in mice and during differentiation of primary human 
muscle cells. Finally, in humans, genetic association studies (>700,000 SNPs) demonstrated 
that the A alleles of rs10505025 and rs4734621 SNPs in the UBR5 gene were strongly 
associated with larger cross-sectional area of fast-twitch muscle fibres and favoured 
strength/power versus endurance/untrained phenotypes. Overall, we suggest that UBR5 is a 
novel E3 ubiquitin ligase that is inversely regulated to MuRF1/MAFbx, is epigenetically 
regulated, and is elevated at both the gene expression and protein level during recovery 
from skeletal muscle atrophy and hypertrophy.  
 
Keywords: UBR5, EDD1, DNA methylation, E3 ubiquitin ligase, hypertrophy, atrophy, 
muscle recovery, epigenetics, remodelling, TTX-atrophy, hindlimb suspension, functional 
overload, synergist ablation, functional-overload, gene expression, pyrosequencing, 
bioengineered muscle, mechanical loading.  
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Introduction 
Proteolysis is the breakdown of proteins within cells. The ubiquitin-proteasome is the main 
system involved in protein turnover (Rock et al., 1994; Cao et al., 2005). In skeletal muscle, 
this system increases protein degradation as it reduces in size (reviewed in (Bodine & 
Baehr, 2014)) and remodels (Yang et al., 2006; Gomes et al., 2012; Slimani et al., 2012). 
Ubiquitin-mediated proteolysis operates via distinctive enzymatic tagging to an area of a 
polypeptide chain using ubiquitin, securing the substrate proteins fate for degradation in the 
proteasome (Glickman & Ciechanover, 2002). Proteins tagged with ubiquitin are then 
recognised by the large 26S protease complex that degrades them into smaller peptides 
(Baumeister et al., 1998). This ubiquitination tagging system is activated by enzymes 
triggered sequentially. The E1 enzyme activates ubiquitin, the E2 enzyme carries and 
conjugates ubiquitin to the E3 enzyme that then catalyses its binding to the designated 
protein substrate for degradation (reviewed in (Metzger et al., 2012)). There are 
approximately 40 E2 and over 600 E3 ubiquitin ligases in the human genome making it an 
extremely complex and relatively uncharacterised system.  
 
Over the past two decades, the E3 ligases in particular have received specific attention in 
skeletal muscle, namely due to the discovery of important E3’s that are selectively 
expressed in this tissue, including: Trim63, renamed muscle specific RING finger protein 1 
(MuRF1); Fbxo32, renamed the F-box containing ubiquitin protein ligase atrogin-1 or Muscle 
Atrophy F-box (MAFbx/Atrogin-1) (Bodine et al., 2001; Gomes et al., 2001). As well as the 
more recently characterised; Fbxo30, renamed muscle ubiquitin ligase of SCF complex in 
atrophy-1 (MUSA1) (Sartori et al., 2013), Parkin and ZNF216 (Hishiya et al., 2006; Furuya 
et al., 2014). MuRF1 contains a RING finger domain, whereas MAFbx/Atrogin-1 and MUSA1 
have an F-box domain (part of the SCF family of E3s). RING fingers form the vast majority of 
all the E3 ligases. RING finger domains are zinc-binding motifs of 40-60 histidine and 
cysteine amino acid residues in a C3HC4 (RING) or C3H2C3 (RING-H2) formation (Bordone & 
Freemont, 1996). E3 RING finger proteins cause ubiquitin to be catalysed indirectly, acting 
as a scaffold that brings E2 proteins together with the substrate (Lorick et al., 1999; Metzger 
et al., 2012). Importantly, E3 ligases MuRF1 and MAFbx/Atrogin-1 have been demonstrated 
to increase rapidly at the gene expression level at around 48 hrs in the time course of 
atrophy in rodents following disuse (e.g. after denervation, hindlimb unloading, tetrodotoxin 
nerve exposure) increasing progressively up to 7-10 days (Bodine et al., 2001; Gomes et al., 
2001; Clavel et al., 2006; Moresi et al., 2010; Fisher et al., 2017). Furthermore, the 
expression of these genes increased in human muscle 48 hrs after spinal cord injury and 14 
 This article is protected by copyright. All rights reserved. 4 
days after limb immobilisation (de Boer et al., 2007; Urso et al., 2007; Gustafsson et al., 
2010). MuRF1 and MAFbx/Atrogin-1 have also been shown to increase after starvation 
induced skeletal muscle atrophy (Gomes et al., 2001; Lecker et al., 2004) and are elevated 
in aging and cachexia (Gomes et al., 2001; Lecker et al., 2004; Clavel et al., 2006; Costelli et 
al., 2006; Raue et al., 2007; Altun et al., 2010). MuRF1 has been suggested to target 
myofibrillar proteins such as titin, nebulin, troponin1 (Witt et al., 2005) and thick filament 
proteins such as myosin-binding protein C (MyBP-C) as well as myosin light chains 1 and 2 
(MyLC1 and MyLC2) for degradation (Cohen et al., 2009), whereas suggested MAFbx 
substrates include the myogenic regulatory factor, MyoD, Myogenin, eukaryotic translation 
initiation factor 3 subunit f (eIF3-f) (Tintignac et al., 2005; Lagirand-Cantaloube et al., 2008; 
Jogo et al., 2009) and the intermediate filament proteins vimentin and desmin (Lokireddy et 
al., 2012). Importantly, knock-down of MuRF1 and MAFbx/Atrogin-1 enzymes render mice 
partially resistant to denervation induced atrophy (Bodine et al., 2001), and MuRF1 knock 
down also prevents atrophy following hindlimb unloading (HU) and glucocorticoid 
treatment (Bodine et al., 2001; Labeit et al., 2010; Baehr et al., 2011). MuRF1 knock-
down can help delay anabolic resistance and maintain muscle mass in aged rodents 
(Hwee et al., 2014). Finally, MUSA1 knockdown using in-vivo electroporation of shRNA 
has been shown to spare muscle mass following denervation and prevent more severe 
atrophy observed in Smad4−/− mice (Sartori et al., 2013). Collectively, these data confirming 
an important function for these E3’s in skeletal muscle atrophy.  
 
Together with RING finger domains, another key group of the E3 enzymes contain HECT 
(homologous to E6-AP carboxy-terminus) domains. The HECT domain of these E3 
enzymes, unlike RING finger family members, directly binds activated ubiquitin to the target 
protein substrate. However, HECT domain E3 ligases remain relatively unstudied in skeletal 
muscle atrophy or remodelling. Interestingly, we have recently demonstrated that a HECT 
domain E3 ligase called UBR5 (aka. EDD1), previously uncharacterized in skeletal muscle, 
is an epigenetically regulated gene (identified using 850K DNA methylation arrays) 
hypomethylated after resistance exercise-induced muscle hypertrophy in humans (termed 
loading/training) (Seaborne et al., 2018b). In this study, resistance exercise-induced 
hypertrophy was followed by complete cessation of exercise and a return of lean leg mass to 
pre-exercise baseline levels (unloading/detraining). In the same participants, a second 
period of resistance exercise-induced hypertrophy (reloading/retraining) ensued, in which the 
greatest increase in lean leg mass was observed. At the DNA level, we discovered that 
UBR5 became hypomethylated during periods of resistance exercise induced hypertrophy 
and returned to baseline levels upon exercise cessation. This oscillating methylation profile 
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was inversely associated with changes in UBR5 expression, suggesting that the transcript 
was epigenetically regulated. Importantly, the largest increases in hypomethylation, gene 
expression and muscle mass were observed after later reloading/retraining. Therefore, the 
level of UBR5 gene expression was positively and strongly correlated with the increases in 
lean leg mass across after training and retraining (Seaborne et al., 2018b). This data 
indicated that UBR5 was an E3 ligase associated with muscle hypertrophy rather than 
muscle atrophy. This was surprising given the well-defined role of the aforementioned E3 
ligases in protein degradation, and therefore suggested that UBR5 may instead be important 
in muscle remodelling and recovery during changes in muscle mass. We therefore aimed to 
investigate the role of UBR5 more extensively during atrophy/injury and recovery from 
atrophy/injury as well as following anabolism, hypertrophy and muscle cell differentiation in 
order to start to characterise its role across these processes. We also aimed to further 
substantiate UBR5’s genetic role in muscle fibre size and physical performance using micro-
array analysis in humans.  
 
Methods 
 
Tetrodotoxin (TTX)- induced atrophy and TTX cessation for recovery in-vivo 
In new analysis of samples derived from previous work carried out by our group (Fisher et 
al., 2017), we assessed UBR5 DNA methylation and gene expression following tetrodotoxin 
(TTX) induced atrophy and recovery of the tibialis anterior (TA) in rats. Briefly, the common 
peroneal nerve in the left hindlimb of adult male Wistar rats was exposed to TTX using an 
implanted subcutaneous mini-osmotic pump (Mini Osmotic Pump 2002, Alzet, Cupertino CA, 
USA) in the scapular region, with a delivery tube leading to a silicone rubber cuff placed 
around the nerve. This delivered 0.5 μl/hr of TTX (350 μg/ml in sterile 0.9 % saline) so that 
the ankle dorsiflexor muscles (TA and extensor digitorum longus/EDL) were silenced but 
normal voluntary plantar-flexion was maintained for a period of 14 days (d). This evoked 
reductions in muscle weight of 7, 29 and 51% and fiber CSA of 18, 42, 69% at 3, 7 and 14 d 
respectively (Fisher et al., 2017). The muscle was then allowed to recover after exhaustion 
in osmotic pump delivery of TTX to the peroneal nerve and allowing normal habitual physical 
activity to resume for a period 7 days post 14 d TTX atrophy (recovery), that resulted in a 52 
and 63% increase after 7 d recovery of muscle weight and fiber CSA respectively versus the 
14 d TTX-induced atrophy timepoint (Fisher et al., 2017). RNA and DNA were isolated from 
the contralateral control (right) limb and from the TTX (left) limb at 3, 7, 14 d (n = 6 for 3/7/14 
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d, n = 4 recovery). Experimental procedures were conducted according to the permissions 
within a project license granted under the British Home Office Animals (Scientific 
Procedures) Act 1986. Wistar rats were sourced from registered breeding colonies at LJMU 
Life Sciences Support Unit and euthanasia was conducted by rising CO2 (100% CO2 at a 
flow rate of approx. 20% of chamber volume) followed by cervical dislocation. 
 
Atrophy induced via continuous low frequency electrical stimulation in-vivo 
In male Wistar rats (3 months of age) under anaesthesia with 2% inhaled isoflurane and 
buprenorphine intramuscular injection at 0.1 mg/kg, a sterilised miniature implantable 
stimulator was inserted into the abdominal cavity and sutured to the abdominal wall, in a 
model previously described (Jarvis et al., 1996). Briefly, in new experimentation, the 
electrodes were tunnelled subcutaneously and placed under (but not touching) the common 
peroneal nerve and sutured to the aponeurosis of the gastrocnemius muscle of the left hind 
limb to keep the electrodes in place, and allow activation of the TA and EDL via the common 
peroneal nerve. Animals were then allowed to recover from the implant procedure for 7 d 
before initiating a continuous low frequency 20 Hz stimulation for a further period of 7 d, 
turned on remotely using a stroboscope to transmit a sequence of light pulses through the 
skin. This resulted in an 12.64% reduction in muscle weight of the TA after 7 d in the 
stimulated versus the contralateral unstimulated right control limb (n = 6 muscle weight, 
Figure 1A), using methodology previously described (Jarvis et al., 1996). Daily stimulation 
was conducted under no anaesthesia and amplitude of nerve stimulation was remotely 
adjusted under careful observation to provide motor-neurone activation without limb 
withdrawal or signs of distress. TA samples were taken from the stimulated and unstimulated 
contralateral limb at the end of the 7 d stimulation protocol. Experimental procedures were 
conducted according to permissions within a project license granted under the British Home 
Office Animals (Scientific Procedures) Act 1986. Wistar rats were sourced from registered 
breeding colonies at LJMU Life Sciences Support Unit and euthanasia was conducted by 
rising CO2 followed by cervical dislocation. 
 
Hindlimb suspension induced-atrophy and recovery in adult and aged animals in-vivo 
The response of hindlimb muscles to unloading and recovery was studied in 9-month (adult) 
and 29-month (aged) male Fischer 344-Brown Norway (F344BN) rats obtained from the 
National Institute of Aging. Using the same samples obtained from previous published 
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experiments (Baehr et al., 2016), we undertook new analysis of UBR5 protein abundance. 
Briefly, hindlimb unloading (HU) was achieved by tail-suspension as previously described 
(Thomason et al., 1987; Baehr et al., 2016), with the rats attached to a swivel (360° rotation) 
mounted plastic bar at the top of the cage in a ∼30° head-down tilt position for a period of 14 
d. Animals were released from the tail suspension on day 15 at which time the rats were 
individually housed and allowed unrestricted cage activity for 3, 7, or 14 days (n = 6/ group). 
Muscle from the medial gastrocnemius (MG) was removed and lysed for protein extraction at 
baseline, 14 d after HU and at 3, 7 and 14 d of reloading/recovery (REL). During tissue 
collection, animals were anesthetized with 2-3% inhaled isoflurane on completion of tissue 
removal, rats were euthanized by exsanguination. All animal procedures were approved by 
the Institutional Animal Care and Use Committee at the University of California, Davis, USA.  
 
Nerve crush injury, atrophy and recovery in-vivo 
Targeted nerve crush in the lower limb muscles of the right leg was accomplished via acute 
10 second crushing of the sciatic nerve in the midthigh region using forceps. The procedure 
was completed under isoflurane anaesthesia (3% inhalation) with the use of aseptic surgical 
techniques. Male mice (C57BL/6; 12 weeks old) purchased from Charles River Laboratories 
were given an analgesic (buprenorphine, 0.1 mg/kg) immediately and for 48 hours following 
the surgery and returned to their cage following recovery. Following completion of the 
appropriate time period (3, 7, 14, 21, 28, 45 and 60 days/d; n = 6/ group), mice were 
anesthetized with 3% isoflurane, and the gastrocnemius complex (GSTC) muscles were 
excised, weighed, frozen in liquid nitrogen, and stored at −80°C for later analysis. On 
completion of tissue removal, mice were euthanized by exsanguination. Prior to tissue 
collection a sciatic nerve test was applied via a single electrical pulse to the sciatic nerve 
through electrodes to observe a twitch response in the hindlimb muscles. Between 21 and 
60 days all animals displayed a twitch, suggesting that neural activity to the hindlimb 
muscles had returned at these time points. A separate untreated cohort of animals (n = 6) 
were used as relevant controls. All animal procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Iowa, Iowa City, USA. 
 
Mechanical loading of bioengineered skeletal muscle in-vitro 
Bioengineered mouse muscle was created using the C2C12 cell line as previously described 
by our group, using a fibrin self-assembling three-dimensional (3-D) model (Turner et al., 
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2019a). Briefly, C2C12 cells were grown on T75’s to approx. 80% confluence whereby 
90,000 cells/ml in 2 ml growth media (GM; 4.5 g/l glucose DMEM that included 4 mM L-
glutamine, 10% hiFBS, 10% hiNBCS, supplemented with an additional 2 mM L-glutamine 
(Girven et al., 2016),100 U/ml penicillin, 100 μg/ml streptomycin, 0.5 mg/ml 6-aminocaproic 
acid, 50 μM L-ascorbic acid, 50 μM L-proline) were seeded onto each sylgard coated 
(Sylgard 184 Elastomer Kit, Dow Corning, MI, USA) 35 mm culture dish containing a pre-
polymerised (10 mins at room temperature and 1hr at 37 degrees) fibrin gel made up of 500 
μl thrombin-solution (10 U/ml thrombin, 8 μl/ml aprotinin at 10 mg/ml) and 200 μl fibrinogen 
(20 mg/ml). GM was changed every 48 h until ~90% confluency was attained. Media was 
then switched to differentiation media (DM; 4.5 g/l glucose DMEM that includes 4 mM L-
glutamine, 2% HS, supplemented with an additional 2 mM L-glutamine, 100 U/ml penicillin, 
100 μg/ ml streptomycin, 1 mg/ml 6-aminocaproic acid, 50 μM L-ascorbic acid, 50 μM L-
proline) for 48 hrs and then then switched to 7% serum (same media constituents as DM 
with 7% serum, 3.5% hiFBS/ 3.5% hiNBCS) maintenance media (MM) to promote myotube 
formation for a further 10 days. Bioengineered muscle constructs were then transferred to 
bioreactor chambers (TC-3 Ebers, Spain, see Figure 4bi) for subsequent loading which 
involved 5 exercises × 4 sets × 10 reps (at 0.4 mm/s with 90 s rest between sets, 3.5 mins 
rest between exercises, totalling a stretch regime of 60 mins) at 10% stretch (1.2 mm) at 
37C / 5% CO2, recently described in full detail (Kasper et al., 2017; Turner et al., 2019a). To 
identify representative gel morphology (seen in Figure 4bi) bioengineered muscle constructs 
were fixed and dehydrated in ice-cold methanol:acetone:TBS (25:25:50) for 15 mins then a 
further 15 mins in methanol:acetone (50:50) only. Following fixation, gels were 
permeabilised (0.2% Triton X-100) in 1 x TBS for 90 mins and incubated overnight (4°C) in 
250 μl Phalloidin-FITC (Sigma Aldrich, P5282) at a concentration of 50 μg/ml. After overnight 
incubation, Phalloidin-FITC was aspirated and gels were washed 3 x TBS before adding 250 
μl of DAPI stain (ThermoFisher, D1306) at a concentration of 300 μM for 90 mins to 
counterstain myonuclei. Myotubes (Phalloidin-FITC, Excitation: 495 nm, Emission: 513 nm) 
and myonuclei (DAPI, Excitation: 358 nm, Emission: 461 nm) were visualised under an 
inverted fluorescence microscope (Nikon, Eclipse Ti-S) and imaged (Nikon, NIS Elements) 
for morphological analysis. RNA was isolated 30 minutes post-stretch to assess UBR5 
transcript expression versus static non-loaded controls.  
 
Intermittent high frequency chronic electrical stimulation induced hypertrophy in-vivo    
In adult male Wistar rats (6 months of age), under anaesthesia with 2% inhaled isoflurane 
and buprenorphine intramuscular injection at 0.1 mg/kg, a sterilised miniature implantable 
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stimulator was inserted into the abdominal cavity and sutured to the abdominal wall with 
electrodes placed near to the common peroneal and tibial nerves. The muscles were 
electrically stimulated to ensure that the dorsiflexors worked against the plantar-flexors, and 
therefore the dorsi-flexors were ‘loaded’. The stimulation consisted of an intermittent regime 
of high frequency (100 Hz) stimulation once a day for 4 weeks (5 sets x 10 reps, each rep 2s 
with 2s rest between reps, and 2.5 minutes rest between sets). Daily stimulation was 
conducted under no anaesthesia and amplitude of nerve stimulation was remotely adjusted 
under careful observation to provide motor-neurone activation without limb withdrawal or 
signs of distress. Following 4 weeks of the above regime there was an average 14% 
increase in muscle weight and an 19% increase in fiber CSA in the TA muscle at the mid-
belly as previously described (Schmoll et al., 2018). DNA and RNA was isolated from TA 
muscle from this original study (Schmoll et al., 2018) from both the stimulated and 
contralateral (unstimulated) control limbs (n = 4) at the end of the 4 weeks electrical 
stimulation protocol. Experimental procedures were conducted according to the permissions 
within a project license granted under the British Home Office Animals (Scientific 
Procedures) Act 1986. Wistar rats were sourced from registered breeding colonies at LJMU 
Life Sciences Support Unit and euthanasia was conducted by rising CO2 (100% CO2 at a 
flow rate of approx. 20% of chamber volume) followed by cervical dislocation. 
 
Synergist ablation/functional overload (FO) in-vivo 
Hypertrophy of the plantaris muscle was induced in male C57BL/6 mice (12 weeks old) by 
surgical removal of synergist muscles (entire soleus and over half of the medial and lateral 
gastrocnemius without damaging the plantaris neural-vascular supply) according to a 
previously validated method termed synergist ablation or functional overload (FO) (McCarthy 
et al., 2011; Bodine & Baar, 2012; Jackson et al., 2012). The same protein lysates at 
baseline (control), 1, 3, 10 and 14 days (d) following FO previously derived in (Baehr et al., 
2014), that demonstrated significant increases in muscle weight of 43 and 65% after 7 and 
14 d respectively, were analysed in new experimentation for UBR5 protein abundance in the 
present study (n = 3 / group).  C57BL/6 mice were purchased from Jackson 
Laboratories. Mice were anaesthetized with 2-3% inhaled isoflurane. Following tissues 
collection, the mice were euthanized by exsanguination. All animal procedures were 
approved by the Institutional Animal Care and Use Committee at the University of California, 
Davis, USA. 
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Human muscle biopsies, cell isolation and differentiation in-vitro 
Human muscle cells were isolated from the vastus lateralis biopsies of 3 healthy young adult 
males (28 ± 11 yr, 73.00 ± 0.91 kg, 177.2 ± 4.3 cm, means ± SD) who were recreationally 
active but had never undergone a period of supervised chronic aerobic or resistance 
exercise. Full biopsy procedure and primary cell isolation procedures are provided in 
(Seaborne et al., 2018a; Seaborne et al., 2018b; Turner et al., 2019a; Turner et al., 2019b). 
Ethical approval was granted by the NHS West Midlands Black Country, UK, Research 
Ethics Committee (NREC approval no. 16/WM/010) as previously reported (Seaborne et al., 
2018b). Briefly, conchotome biopsies were immediately transferred to a sterile class II BSC 
in pre-cooled transfer media (TM; Hams F-10, 2% hi-FBS, 100 U/ml penicillin, 100 μg/ml 
streptomycin and 2.5 µg/ml amphotericin-B) and any connective/adipose tissue removed 
using a sterile scalpel on a petri dish in the same transfer media. Biopsies were then washed 
in sterile PBS (plus 100 U/ml penicillin, 100 µg/ml streptomycin and 2.5 µg/ml amphotericin-
B), scissor minced in the presence of 0.05% Trypsin/0.02% EDTA and then titrated on a 
magnetic stirring platform at 37°C, with this procedure repeated twice. The supernatant 
following each of these procedures was then collected and pooled with horse serum at 10% 
of the total supernatant volume to neutralize the trypsin. The supernatants from each 
treatment were then pooled and centrifuged at 340 rcf for 5 minutes to generate a cell pellet. 
The supernatant was plated in a T25 (as a backup source of any cells remaining) and the 
cell pellet was resuspended on a separate T25, both in growth media/GM (GM; Ham’s F10 
nutrient mix supplemented with 10% hi-NCS, 10% hi-FBS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 2.5 µg/ml amphotericin B and 5 mM L-glutamine). Once confluent cells were 
split onto larger T75’s to generate enough cells to perform differentiation experiments. 
Human derived muscle cells were then seeded onto gelatin coated 6 well plates, at a density 
of 9x105 cells/ml in 2 ml of GM for 24 hrs prior to removal of GM, 3 x PBS washes and 
transfer to differentiation media (DM; Ham’s F10 nutrient mix supplemented with 2% hiFBS, 
100 U/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml amphotericin B and 5 mM L-
glutamine) for a period of 7 days. Cells were lysed for protein at 0 hrs (30 minutes in DM), 72 
hrs and 7 days after transfer to DM. All experiments were carried out below passage 10 to 
prevent senescence.  
 
Human micro-array methods and association analyses 
The human association studies involved 357 Russian international-level athletes (age 24.0  
3.6 years; 192 males and 165 females), 84 physically active men and 173 controls (83 males 
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and 90 females). The athletes were stratified into 4 groups according to type, intensity, and 
duration of exercise. The first group (n = 142) included long-distance endurance athletes (3-
10 km runners, biathletes, 5-10 km skaters, cross-country skiers, marathon runners, 0.8-25 
km swimmers, race walkers, and triathletes. The second group (n = 115) comprised of 
sprinters (50-100 m swimmers, 200 m kayakers and canoers, sprint cyclers, 100-400 m 
runners, 500-1000 m skaters and short-trackers). The third group (n = 73) included strength 
athletes (powerlifters and weightlifters). The fourth group comprised explosive power 
athletes with predominantly anaerobic energy production (arm-wrestlers, track and field 
jumpers, heptathletes / decathletes and throwers). There were 198 athletes classified as 
‘elite’ (prize winners of major international competitions). There were 159 athletes classified 
as ‘sub-elite’ (participants in international competitions). Physically active men (n=84; age 
33.1  7.3 years, height 180.1  6.2 cm, weight 81.0  10.4 kg were involved in the muscle 
biopsy study. Russian controls were 173 unrelated citizens of Russia without any 
competitive sport experience. The athletes and controls were all Caucasians of Eastern 
European descent. The overall study was approved by the Ethics Committee of the 
Physiological Section of the Russian National Committee for Biological Ethics (approval 
number 2018/08) and Ethics Committee of the Federal Research and Clinical Centre of 
Physical-Chemical Medicine of the Federal Medical and Biological Agency of Russia 
(approval number 2017/04). Written informed consent was obtained from each participant. 
The study complied with the guidelines set out in the Declaration of Helsinki and ethical 
standards in sport and exercise science research. 
 
Molecular genetic analysis in all Russian athletes, physically active men and controls was 
performed with DNA samples obtained from leukocytes (venous blood). Four ml of venous 
blood were collected in tubes containing EDTA (Vacuette EDTA tubes, Greiner Bio-One, 
Austria). Blood samples were transported to the laboratory at 4°C and DNA was extracted 
on the same day. DNA extraction and purification were performed using a commercial kit 
according to the manufacturer's instructions (Technoclon, Russia) and included chemical 
lysis, selective DNA binding on silica spin columns and ethanol washing. Extracted DNA 
quality was assessed by agarose gel electrophoresis. HumanOmni1-Quad BeadChips 
(Illumina Inc, USA) were used for genotyping of 1,140,419 SNPs in athletes and controls and 
HumanOmniExpress BeadChips (Illumina Inc, USA) were used for genotyping of > 700,000 
SNPs in participants of the Muscle Fiber Study (84 physically active men). The assay 
required 200 ng of DNA sample as input with a concentration of at least 50 ng/µl. Exact 
concentrations of DNA in each sample were measured using a Qubit Fluorometer 
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(Invitrogen, USA). All further procedures were performed according to the instructions of the 
Infinium HD Assay.  
 
Evaluation of muscle fiber composition and cross-sectional area 
Samples of the vastus lateralis muscle of Russian athletes were obtained with the Bergström 
needle biopsy procedure under local anaesthesia with 1% lidocaine solution. After this 
procedure, serial cross-sections (sections cut after on another) (7 μm) were obtained from 
frozen samples using a microtome (Leica Microsystems, Wetzlar, Germany). The sections 
were thaw-mounted on Polysine glass slides, kept for 15 min at RT and incubated with in 
PBS (3  5 min). Then one of the serial sections was incubated at RT in primary antibody 
against a slow isoform of the myosin heavy chains and the second serial section against a 
fast isoform of the myosin heavy chains (M8421, 1:5000; M4276; 1:600, respectively; Sigma-
Aldrich, USA) for 1 h and incubated in PBS (3  5 min). After this, the serial sections were 
incubated at RT in a secondary antibody conjugated with FITC (F0257; 1:100; Sigma-
Aldrich) for 1 hr. The sections were then washed in PBS (3  5 min), placed in mounting 
media and covered with a cover slip. The image was captured using a fluorescent 
microscope Eclipse Ti-U (Nikon, Japan). All analyzed images contained > 100 fibers. An 
example of stained images for slow and fast fibres can be seen in Figure 5A). The ratio of 
the number of stained fibers to the total fiber number was calculated. Fibers stained in serial 
sections with antibodies against both slow and fast isoforms were considered as hybrid 
fibers. The cross-sectional area (CSA) of fast and slow fibers was evaluated using ImageJ 
software (NIH, USA). 
 
Strength measurement 
Evaluation of strength in elite Russian weightlifters was assessed by their performance in 
snatch, and clean and jerk (best results in official competitions including Olympic Games, 
Europe and World Championships). The total weight lifted (in kg) was multiplied by the Wilks 
Coefficient (Coeff) to find the standard amount lifted normalised across all body weights. 
      
   
                    
, where x is the body weight of the weightlifter in kilograms. 
Values for males were: a = -216.0475144; b = 16.2606339; c =-0.002388645; d = -
0.00113732; e = 7.01863E-06; f = -1.291E-08. Values for females were: a = 
594.31747775582, b = -27.23842536447; c = 0.82112226871; d = -0.00930733913; e = 
4.731582E-05; f = -9.054E-08. 
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Gene expression by rt-qRT-PCR 
Tissue from TTX atrophy/recovery, high frequency chronic intermittent electrical stimulation, 
continuous low frequency ‘overtraining’ stimulation and bioengineered muscle was 
homogenised in Tri-Reagent (Invitrogen, Loughborough, UK) for 45 seconds at 6,000 rpm x 
3 (5 minutes on ice in between intervals) using a Roche Magnalyser instrument (Roche, 
Germany) and homogenization tubes containing ceramic beads (MagNA Lyser Green 
Beads, Roche, Germany). Human cells from differentiation experiments in monolayer were 
also lysed in Tri-Reagent for 5 minutes before being removed from the wells using a sterile 
cell scraper. RNA was then isolated from all these models using the manufacturer’s 
instructions for Tri-Reagent. In a one-step reaction (reverse transcription and PCR) qRT-
PCR was performed using a QuantiFastTM SYBR
® 
Green RT-PCR one-step kit on a 
Rotorgene 3000Q, with a reaction setup as follows; 4.75 μl experimental sample (7.36 ng/μl 
totalling 35 ng per reaction), 0.075 μl of both forward and reverse primer of the gene of 
interest (100 μM stock suspension), 0.1 μl of QuantiFast RT Mix (Qiagen, Manchester, UK) 
and 5 μl of QuantiFast SYBR Green RT-PCR Master Mix (Qiagen, Manchester, UK). 
Reverse transcription initiated with a hold at 50oC for 10 minutes (cDNA synthesis) and a 5-
minute hold at 95oC (transcriptase inactivation and initial denaturation), before 40-45 PCR 
cycles of; 95oC for 10 sec (denaturation) followed by 60oC for 30 secs (annealing and 
extension). Primer sequences for genes of interest and reference genes across mouse, rat 
and human samples are included in Table 1. All genes of interest and reference gene 
primers across species demonstrated no unintended targets via BLAST search and yielded 
a single peak after melt curve analysis conducted after the PCR step above. All relative gene 
expression was quantified using the comparative Ct (∆∆Ct) method (Schmittgen & Livak, 
2008). For rat experiments that included gene expression (e.g. TTX atrophy-recovery, 
continuous low frequency electrical stimulation ‘overtraining’-induced atrophy and high 
frequency intermittent electrical stimulation induced hypertrophy), the contralateral control 
limb was used in ∆∆Ct equation as the calibrator condition. For bioengineered mouse muscle 
the pooled value from the static unloaded controls were used as the calibrator condition due 
to demonstrating low variation in Ct value (mean ± SD, 18.5 ± 0.8, 4.3% variation). Finally, 
for human cell differentiation the 0 hrs control sample within each subject was used as the 
calibrator. The average Ct value for the human cell differentiation experiments (RPL13a), rat 
(Polr2a) and mouse (Pol2rb) reference genes were also consistent across all samples and 
experimental conditions (human cell differentiation (mean Ct ± SD): 14.8 ± 0.5, rat TTX 21.8 
± 1.1, rat 20Hz continuous low frequency stimulation ‘overtraining’ 21.8 ± 1, rat intermittent 
high frequency 100Hz stimulation 23.2 ± 0.7, mouse bioengineered muscle 18.3 ± 0.7) with 
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small variations of 3.5, 4.9, 4.7, 2.8, 3.9% respectively. The average PCR efficiencies of 
UBR5 (human cell differentiation 91.8%, rat TTX 91.7%, rat 20Hz continuous low frequency 
stimulation ‘overtraining’ 92.5%, rat intermittent high frequency 100Hz stimulation 90.4%, 
mouse bioengineered muscle 93.8%) were comparable with the human reference gene 
RPL13a (97.2%), rat reference Pol2ra gene (rat TTX 93.9%, rat 20Hz continuous low 
frequency stimulation ‘overtraining’ 93.5%, rat intermittent high frequency 100Hz stimulation 
90.9%) and mouse Pol2rb gene (mouse bioengineered muscle 91.6%).  
 
Finally, for nerve crush injury model experiments, frozen muscle powder was homogenised 
using RNAzol RT reagent (Sigma-Aldrich, St Louis, USA) according to the manufacturer's 
instructions. cDNA was synthesized using a reverse transcription kit (iScriptTm cDNA 
synthesis kit, Bio-rad, USA) from 1 μg of total RNA. 10 μl PCR reactions were setup as 
follows: 2 μl of cDNA, 0.5 μl (10 μM stock) forward and reverse primer, 5 μl of Power 
SYBRTM Green master mix (Thermofisher Scientific, USA)) and 2 μl of RNA/DNA free water. 
Gene expression analysis was then performed by quantitative PCR (qPCR) on a 
Quantstudio 6 Flex Real-time PCR System (Applied Biosystems) using the UBR5 mouse 
primers in Table 1 (also used in the other mouse bioengineered muscle analysis). PCR 
cycling was as follows hold at 50oC for 5 minutes, 10-minute hold at 95oC, before 40 PCR 
cycles of; 95oC for 15 sec followed by 60oC for 1 minute (combined annealing 
and extension). Primer testing in these nerve crush samples yielded 89.04% efficiency for 
UBR5. As above, melt curve analysis at the end of the PCR cycling protocol yielded a single 
peak. For these experiments due to reference gene instability, after first assessing total 
RNA/mg tissue and then taking the ∆Ct expression value, the mRNA was described relative 
to tissue weight, and then described as fold change relative to control muscles as previously 
described (Heinemeier et al., 2009) an analysis used extensively by the group previously 
(Baehr et al., 2016; Baehr et al., 2017; Hughes et al., 2018). 
 
DNA methylation by pyrosequencing 
DNA samples from cells and tissue were isolated using Qiagen’s DNA easy blood and tissue 
kit (Manchester, UK) and bisulfite converted using Zymo Research EZMethylation Kit (Zymo 
Research, Irvine, CA, USA) as per manufacturer’s instructions. Prior to DNA isolation tissue 
samples were homogenized for 45 seconds at 6,000 rpm x 3 (5 minutes on ice in between 
intervals) in the lysis buffer (buffer ATL and protinase K) provided in the above DNA isolation 
kits using a Roche Magnalyser instrument and homogenization tubes containing ceramic 
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beads (Roche, UK). UBR5 PCR primers and pyrosequencing primers were purchased from 
EpigenDX (Hopkinton, MA, USA), rat assay no: ADS5785 and mouse assay no: ADS5784, 
summarized in Table 2. PCR reactions were setup as follows; 3 μl of 10X PCR buffer 
(containing 15 mM MgCl2), plus an additional 1.8 μl of 25 mM MgCl2, 0.6 μl of 10 mM 
dNTPs, 0.15 μl HotStar Taq Polymerase (5 U/µl), 1 µl of bisulfite treated DNA and 0.6 μl of 
forward and reverse primer (10 µM). One primer was biotin-labelled and HPLC purified in 
order to facilitate purification of the final PCR product using streptavidin sepharose beads 
(see below). Following an initial denaturation incubation at 95°C for 15-min, for the Rat 
UBR5 assay; 45 cycles of denaturation at 95°C for 30 s; 51°C for 30 s (annealing), 68°C for 
30 s (extension) were performed, with all PCR cycles followed by a final 5 minutes at 68°C. 
The mouse UBR5 assay had the same cycling parameters except for the annealing step that 
was conducted at 51°C for 30 s. PCR products were then bound to 2 µl Streptavidin 
Sepharose HP (GE Healthcare Life Sciences) in 40 µl Binding Buffer (Pyromark binding 
buffer, Qiagen, Manchester UK) and 25 µl Milli-Q-water. After which the immobilized PCR 
products were purified, washed, denatured with a 0.2 μM NaOH solution and rewashed 
using the Pyrosequencing Vacuum Prep Tool (Pyrosequencing, Qiagen, Manchester, UK), 
as per the manufacturer’s instructions. The denatured and washed PCR products were then 
placed in annealing buffer (Pyromark annealing & wash buffers, Qiagen, Manchester UK) 
with 0.5 μM sequencing primer at 75°C for two minutes on a heating block and the block 
then turned off for 10 minutes with the samples left in the block and then a further 10-15 
minutes to cool at room temperature. Sequencing of the single stranded products yielded 
after PCR was conducted on a PSQ96 HS System (Qiagen, Manchester, UK) using 
Pyromark Gold Q24/Q96 reagents (Qiagen, Manchester, UK) following the manufacturer’s 
instructions. Methylation status of the individual CpG sites was identified as an artificial C/T 
SNP using QCpG software (Pyrosequencing, Qiagen, UK). Then % methylation of each CpG 
site was then calculated as a proportion of the methylated alleles divided by the sum of all 
methylated and unmethylated alleles, with the average methylation also then calculated 
across all CpG sites analysed within each gene. Non-CpG cytosines were included as 
internal controls for detection of incomplete bisulfite conversion. Furthermore, unmethylated 
and methylated DNA strands were included as controls after each PCR and bias testing was 
conducted by unmethylated control DNA mixed with in vitro methylated DNA at different 
ratios (0%, 5%, 10%, 25%, 50%, 75% and 100%). All supporting information for gene 
assays, including assay genomic sequence, bisulfite converted sequence and 
pyrosequencing dispensation order, CpG island locations, position from transcriptional start 
site and CpG ID numbers are given in Table 2.  
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SDS page and western blotting 
For UBR5 protein analysis from the hindlimb unloading, nerve crush and functional overload 
models, medial gastrocnemius (MG), gastrocnemius complex (GSTC) and plantaris muscle 
respectively were homogenized in sucrose lysis buffer (50 mM Tris pH 7.5, 250 mM sucrose, 
1 mM EDTA, 1 mM EGTA, 1% Triton X 100, 50 mM NaF). The supernatant was collected 
following centrifugation at 8,000 g for 10 minutes and protein concentrations were 
determined using the PierceTM 660 nm protein assay reagent (Thermo Scientific, Waltham, 
USA). Twelve micrograms of protein were subjected to SDS-PAGE on 4-20% Criterion TGX 
stain-free gels and transferred to polyvinylidene diflouride membranes. Membranes were 
blocked in 3% non-fat milk in Tris-buffered saline (TBS) with 0.1% Tween-20 (TBST) added 
for one hour and then probed with primary antibody overnight at 4°C (monoclonal UBR5 
antibody, D6087; Cell Signalling Technology 1:500). Membranes were washed and 
incubated with HRP-conjugated secondary antibodies at 1:10,000 for one hour at room 
temperature. Immobilon Western Chemiluminescent HRP substrate was then applied to the 
membranes prior to image acquisition. Image acquisition and band quantification were 
performed using the Azure C400 System and Image Lab 6.0.1 software, respectively. Total 
protein loading of the membranes captured from images using stain-free gel technology 
(described above) was used as the normalization control for all blots for data from the 
hindlimb unloading, nerve crush and functional overload models. The same control lysates 
were run on two western blots to allow for quantification of UBR5 protein across multiple 
time points with the nerve crush injury analysis. 
 
For human cell differentiation experiments, cell monolayers were lysed with trypsin and 
centrifuged at 18,000g to pellet the cells. The supernatant was discarded, and the remaining 
pellet was immediately frozen in liquid nitrogen. For the isolation of total protein, cell pellets 
were re-suspended in ice cold radioimmunoprecipitation assay (RIPA) buffer (Thermo 
Scientific) containing protease and phosphatase inhibitor cocktail (cOmplete Mini Protease 
Inhibitor Cocktail; Roche). The cell solution was kept on ice for ten minutes, following which 
samples were sonicated and vortexed before total protein content was determined by a 
bicinconinic acid assay (BCA) (Pierce, Thermo Fisher). Samples were then diluted to a final 
concentration of 1 µg/µl in 4x Laemmli buffer (Bio-Rad) and ultra-pure water and boiled for 
10 minutes to denature proteins. For the determination of UBR5 abundance, equal amounts 
of protein (20 ug) were separated using SDS-PAGE on 6% gels at a constant voltage of 100 
V per gel. Protein was then transferred onto a nitrocellulose membrane by wet transfer at 30 
V overnight at 4oC in Towbin buffer. Protein transfer was assessed by ponceau red staining 
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(Sigma-Aldrich). Membranes were blocked with 5% bovine serum albumin (BSA) in TBST 
and then incubated overnight at 4oC with a monoclonal UBR5 antibody (D6087; Cell 
Signalling Technology) and GAPDH (14C10; Cell Signalling Technologies) at a working 
concentration of 1:500 and 1:1000 in 5% BSA-TBST, respectively. Following 3x10 min TBST 
washes, membranes were washed in TBST 3x10 minutes prior to incubation in appropriate 
horse radish peroxidase-conjugated secondary antibody at room temperature for one hour. 
Chemiluminescent substrate was added to membranes and visualised in a Chemi-doc MP 
imaging system (Bio-Rad). Integrated density was determined for each band and all bands 
were normalized to GAPDH. 
 
Muscle specific knock-down of UBR5 for antibody validation 
To confirm that the UBR5 antibody above (monoclonal UBR5 antibody, D6087; Cell 
Signalling Technology) used in the western blots was specific for UBR5. We use an RNAi 
system which was designed and purchase via Invitrogen (Massachusetts, USA). Specifically, 
the negative control RNAi plasmid was described previously (Ebert et al., 2012) and 
encodes emerald green fluorescent protein (EmGFP) and a non-targeting pre-miRNA under 
bicistronic control of the CMV promoter in the pcDNA6.2GW/EmGFP-miR plasmid 
(Invitrogen). The UBR5 RNAi plasmid encodes EmGFP and an artificial pre-miRNA targeting 
mouse UBR5 under bicistronic control of the CMV promoter; it was generated by ligating the 
Mmi571982 oligonucleotide duplex (Invitrogen) into the pcDNA6.2GW/EmGFP-miR 
plasmid. The designed plasmids were incubated at 37°C overnight with TopOne Shot cells 
(Thermofisher Scientific cat no. C404010) on LB Agar Bacterial resistant plates (50 µg/ml 
Spectinomycin Sigma Aldrich cat no. S4014) in SOC medium (Invitrogen cat no. 15544-034), 
with isolated colonies then incubated/grown overnight in an orbital shaker at 37°C in falcon 
tubes. Bacteria where then pelleted at 6800 g for 1 min. Plasmid DNA from the bacteria was 
then prepared using a maxi prep kit (Nucleobond Xtra Maxi EF, Cat no. 740424.50 Machery-
Nagel, USA) as per manufacturer’s instructions. The electroporation of DNA plasmids was 
performed as previously described (Ebert et al., 2010; Hughes et al., 2018). Briefly, after a 2 
hr pre-treatment with 0.4 units/µl of hyaluronidase, 20 µg of mIR RNAi or negative control 
plasmid was injected into the TA muscle in C57/BL6 male mice (12-16 week-old, n = 
5; purchased from Charles River Laboratories) and the hind limbs were placed between two-
paddle electrodes and subjected to 10 pulses (20 msec) of 175 V/cm using an ECM-830 
electroporator (BTX Harvard Apparatus). It has been previously demonstrated that the use of 
a pre-treatment with hydaluronidase allows for enhanced levels of transfected muscle 
without increased levels of muscle damage during the electroporation process (McMahon et 
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al., 2001). The TA muscle was harvested for western blot analysis after 7 days post 
electroporation. On completion of tissue removal, mice were euthanized by 
exsanguination. All animal procedures were approved by the Institutional Animal Care and 
Use Committee at the University of Iowa, Iowa City, USA.  We subsequently confirmed that 
UBR5 protein abundance was significantly reduced following injection of the UBR5 RNAi  
plasmid into basal skeletal muscle (Figure 1B). 
 
Statistics 
TTX atrophy/recovery, FO induced hypertrophy and nerve crush models used a two-way 
ANOVA with an appropriate post-hoc correction (Fishers LSD). Human cell differentiation 
experiments were analysed using a one-way ANOVA with Fisher LSD post-hoc test. Those 
with an experimental group versus a relevant control were analysed using t-tests (chronic 
low frequency electrical stimulation induced atrophy, intermittent high frequency- electrical 
stimulation induced hypertrophy, loading of bioengineered muscle, UBR5 antibody 
validation). Biological repeat numbers (n) are specific in the methods sections or associated 
figure legends. Human microarray and association study data were analysed using PLINK 
v1.90, R (version 3.4.3), and GraphPad InStat (GraphPad Software, Inc., USA) software. 
Differences in phenotype between different genotype groups were analysed using Wald test 
(for three genotypes). Allele frequencies between groups of athletes and controls were 
compared by χ2 testing. P values  0.05 were considered statistically significant. In all animal 
experimentation both mice and rats were allowed access to food and water ad libitum. 
 
Results  
UBR5 following skeletal muscle atrophy and recovery 
Utilising a novel in-vivo model of disuse, whereby the common peroneal nerve of Wistar rats 
was exposed to tetrodotoxin (TTX) for 3, 7 and 14 days, we were able to successfully induce 
progressive skeletal muscle atrophy, as we previously described (Fisher et al., 2017). Here, 
we reanalyzed RNA/DNA from these samples and identified that UBR5 gene expression 
significantly increased early in the time-course of atrophy (3 days, p = 0.04), coincident with 
significant hypomethylation of the UBR5 promoter (p = 0.004, Figure 2A). UBR5 gene 
expression remained elevated at 7 days following TTX induced atrophy (p = 0.04) but 
reduced later at 14 days, by which time the most extensive muscle mass loss occurred (51% 
loss in muscle weight), suggesting that increased UBR5 may be associated with early 
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remodelling as a result of atrophy, but not later in the timecourse where the most extensive 
atrophy occurred. To further support and investigate these findings, we examined a 
secondary muscle mass loss stimulus in-vivo. We exposed Wistar rats to continuous low 
frequency electrical stimulation (20 Hz) for 7 days to mimic a model of over-use induced 
atrophy, which we successfully accomplished (12.64% reduction in muscle weight; Figure 
1A). Interestingly, we identified that UBR5 did not significantly increase compared to control 
(p = N.S), whereas MuRF1 and MAFbx were significantly increased (Figure 2B; MuRF1 p = 
0.01, MAFbx P = 0.03). 
 
To examine the temporal pattern of UBR5 during recovery of skeletal muscle, we utilised our 
14 d TTX atrophy model with an extended 7 day TTX cessation period to allow recovery 
from atrophy. This model successfully recovered skeletal muscle mass and CSA by 52 and 
63% respectively (Fisher et al., 2017). In this recovery model, we identified significant 
hypomethylation of UBR5 promoter (p = 0.04, Figure 2A) with an average increase in gene 
expression of UBR5 that did not quite reach significance (p = 0.1; Figure 2A & C). 
Importantly, MuRF1 and MAFbx were also significantly increased at the gene expression 
level at 3 and 7 days post TTX-induced atrophy (all p  0.01), as previously described in 
(Fisher et al., 2017), yet these E3 ligases were upregulated to a greater extent (larger fold 
change) over the time course of atrophy than UBR5 (Figure 2C), and importantly were 
downregulated at the gene expression level during recovery. During recovery of muscle, 
UBR5 showed a trend for upregulation (1.91 fold) (albeit non-significantly p = 0.1) versus 
MuRF1 and MAFbx that were supressed below baseline levels (downregulated) that resulted 
in a reduction vs. the 14 d TTX atrophy timepoint (p = 0.08, Figure 2C). This pattern of UBR5 
upregulation and MuRF1 and MAFbx suppression during muscle growth was also observed 
after chronic intermittent stimulation induced hypertrophy in rats (p = 0.02, described below 
in the results and depicted in Figure 4ci). Overall, these data suggest that UBR5 
hypomethylation (significant) and an increase in gene expression (non-significant/p = 0.1) 
were associated with recovery from atrophy and muscle growth (Figure 2A & C).  
 
It is worth noting that in the TTX model, only 7 days of recovery was sufficient to reverse a 
loss of approximately half the weight of the TA seen after 14d of TTX.  Therefore, this could 
be an explanation for observing significant hypomethylation (that precedes gene expression) 
yet a non-significant average increase in UBR5 gene expression itself. To further investigate 
changes in UBR5 gene and protein expression, we used another well characterised model of 
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disuse atrophy and recovery, hind-limb unloading (HU) and recovery/reloading. In this model 
we analysed the medial gastrocnemius (MG) of adult rats that has previously been 
characterised to demonstrate a full recovery of mass after 14 days following resumed 
habitual physical activity (reloading) post HU induced-atrophy (Baehr et al., 2016). 
Furthermore, as aging results in reduced muscle mass and an impaired recovery from 
atrophy (Baehr et al., 2016) versus adult rats, we also examined changes in UBR5 in 
response to HU atrophy and reloading (recovery) in aged rats. Indeed, following 14 days of 
hind-limb suspension in adult and aged rats, UBR5 protein increased early (3 days, albeit 
non-significantly) during atrophy but returned to baseline by 7-14 days in both adult and 
aged skeletal muscle (Figure 2D & E adult and aged respectively). Importantly, during 
recovery of the MG following hindlimb unloading, the largest increase in UBR5 protein was 
observed, demonstrating significant increases at 7 and 14 days post loading in young adult 
(p = 0.057 at 14 d) and aged rats (both p = 0.02 at 7 and 14 d, Figure 2D & E). Overall, 
these data suggest that UBR5 protein increased in abundance and was associated with 
early remodelling during atrophy, similarly to the mRNA responses observed in the TTX 
atrophy model, and importantly were associated with muscle growth and remodelling during 
the reloading/recovery period in both adult and aged rats. 
 
UBR5 after nerve crush injury  
Because increased UBR5 was associated with recovery from atrophy we further sought to 
characterise its changes in a relevant muscle injury model of atrophy/recovery using a nerve 
crush approach. The sciatic nerve in the right lower limb of C57BL/6 mice was crushed 
resulting in denervation and subsequent reinnervation of the lower limb muscles by their 
original motoneurons. This model resulted in a significant reduction in weight of the 
gastrocnemius complex (GSTC) at 7, 14, 21 and 28 d (all p  0.05), the largest reduction 
(38% in muscle weight) occurring prior to reinnervation at 14 days post nerve crush injury 
(Figure 3A). The muscle fully recovered after 48 - 60 days (31 - 46 days after maximal 
atrophy) demonstrated by no significant changes vs. baseline controls (at 45 and 60 days, 
both p  0.05). As with TTX and HU atrophy, UBR5 gene expression and protein abundance 
significantly increased early 3 days following nerve crush injury (Figure 3B gene expression, 
Figure 3D protein abundance, all P = 0.001). Furthermore, UBR5 gene expression dropped 
below baseline after 7 days (Figure 3B), whereas MuRF1 and MAFbx remained elevated 
(Figure 3C & D, albeit not significantly vs. baseline controls, they were significantly elevated 
vs. UBR5 at 7 days, both p = 0.01 for both MuRF1/MAFbx vs. UBR5). However, unlike 
recovery from TTX atrophy or HU during the recovery period, after 14 to 60 days of nerve 
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crush injury, gene expression did not increase (Figure 3B) but significantly decreased in a 
similar fashion to MuRF1 and MAFbx (Figure 3C & D, all P = 0.001). However, importantly 
(and in an inverse relationship to UBR5 gene expression), protein abundance of UBR5 
significantly increased over the time-course of recovery from nerve crush (Figure 3E) 
culminating in significant increases at 28 and 45 d (both P = 0.001), similar to the increase 
demonstrated above following recovery from HU. 
 
UBR5 following skeletal muscle anabolism and hypertrophy 
Our recently published data in humans suggests that UBR5 hypomethylation (via 850K DNA 
methylation arrays) and increased gene expression are associated with hypertrophy in 
humans following training and retraining (re-depicted in Figure 4A), with increased UBR5 
gene expression positively correlating with increases in lean mass in humans (Seaborne et 
al., 2018b). In the present study, we demonstrate that following an acute anabolic 
mechanical loading regime in mouse bioengineered muscle, there was also a significant 
increase (1.58 fold, p = 0.02) in UBR5 gene expression, as well as MAFBx (1.4 fold, P = 
0.03) with a trend for increased expression of MuRF1 (1.77 fold, p = N.S) (all Figure 4Bi & 
Bii). Interestingly, this increase in UBR5 was similar to the fold change increase (1.71 fold) 
we reported previously, in humans after acute resistance exercise (Seaborne et al., 2018b) 
(Figure 4Bi). In this previous paper (Seaborne et al., 2018b), we identified that CpG 
methylation change of UBR5 did not change following the acute exercise stimulus (only after 
chronic training). We therefore examined promotor methylation of UBR5 in our mechanically 
loaded bioengineered mouse model to see if these findings translated across different 
models and species. In accordance with this, we identified that only 1 of the 6 CpG sites 
investigated in the UBR5 promoter were hypomethylated and the rest were hypermethylated 
following the acute anabolic loading stimulus, all non-significantly (data available on 
request). Further, in our original article, we showed an increase in gene expression following 
repeated/chronic resistance exercise (Seaborne et al., 2018b), redrawn in Figure 4A). In an 
attempt to further support these findings, we reanalysed samples from an in-vivo rat model 
of chronic intermittent electrical stimulation induced hypertrophy, alongside a 14% increase 
in muscle weight of the TA (Schmoll et al., 2018). Here we confirmed a similar trend as after 
human hypertrophy demonstrated previously ((Seaborne et al., 2018b), redrawn in Figure 
4A), with a significant increase in gene expression (Figure p = 0.02), and an average global 
reduction in methylation of the UBR5 promoter that did not reach significance (Figure 4Ci). 
Similarly, to our analysis following atrophy and recovery, we examined whether gene 
expression changes in UBR5 were similar or different to the other well-known E3 ubiquitin 
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ligases, MuRF1 and MAFbx. Interestingly, while we observed a significant increase in UBR5 
gene expression in the intermittent electrically stimulated hypertrophy model (Figure 4Ci), 
MuRF1 and MAFbx were unchanged in the same model of hypertrophy (Figure 4Cii). 
Therefore, all the E3 ligases were increased after acute mechanical loading but only UBR5 
was increased, without an increase in MuRF1/MAFbx, at the gene expression level after 
chronic stimulation induced hypertrophy. 
 
We next sought to determine whether the DNA methylation and gene transcript changes 
observed was related to changes in UBR5 protein abundance using an established model 
(synergist ablation or functional overload/FO) of load induced hypertrophy of the plantaris 
muscle in mice. We determined, that after a significant reduction of UBR5 protein 1 d after 
FO (p = 0.02), UBR5 was increased rapidly and significantly at the protein level at 3, 7 and 
14 days over the time-course of hypertrophy (Figure 4D; all p= 0.001) with previously 
determined corresponding significant increases in muscle weight (43 and 65% at 7 and 14 
days respectively, (Baehr et al., 2014)).  
 
Finally, given the differentiation of satellite cells are important for muscle regeneration, and 
because previous data has described a role for UBR5 in the differentiation of smooth muscle 
(Hu et al., 2010)), we decided to analyse the temporal gene expression and protein pattern 
of UBR5 using primary human derived cells over a 7-day time-course of differentiation. 
Herein we demonstrated that cells increasing in morphological differentiation across the time 
course of 0, 72 hrs and 7 d (Figure 4Ei), with gene expression increases in MyoD, Myogenin 
and MYHC2, significant increases in MYHC1 (P = 0.04) and reductions in Myf5 (p = 0.06) 
(Figure 4E ii), did not demonstrate significant increase in UBR5 at the gene expression level 
(data available on request). However, UBR5 protein increased significantly at 72 hrs (p = 
0.01) and 7 days (p = 0.02) across the time course of differentiation versus 0 hrs (Figure 4E 
iii). These data suggest that UBR5 gene expression increased after both acute loading of 
bioengineered muscle in-vitro and chronic intermittent electrical stimulation induced 
hypertrophy in-vivo yet was without changes in mRNA expression during human muscle cell 
differentiation. Furthermore, UBR5 increases in protein abundance after hypertrophy in-vivo 
and across the time-course of human muscle cell differentiation. 
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Genetic Association Studies identified that genetic variants of the UBR5 gene were 
associated with muscle fiber size in physically active men and strength / power athlete status 
Given the increase in gene expression and protein abundance of UBR5 in the above rodent 
models of hypertrophy, as well as our previous studies in humans demonstrating a strong 
correlation for UBR5 gene expression with lean leg mass, we tested the hypothesis that 
genetic variations of the UBR5 gene might be associated with muscle hypertrophy and 
strength/power related phenotypes. Firstly, we identified genetic variations in the UBR5 gene 
that were associated with altered UBR5 gene expression in humans using GTEx (Battle et 
al., 2017). Using this approach, we identified 13 (rs10110916, rs34695816, rs4302812, 
rs4621773, rs4734621, rs4734624, rs61504846, rs74195880, rs7814681, rs7844623, 
rs7845636, rs9693239, rs9694458) single nucleotide polymorphism (SNPs) that were 
located in close proximity (i.e., in high linkage disequilibrium) near UBR5 gene and were 
significantly (P≤10-5-10-6) associated with UBR5 gene expression in human skeletal muscle. 
Of those, rs4734621 was available for genotyping in the athletic cohorts and controls using 
micro-array analysis. According to the GTEx, the A allele of the rs4734621 SNP is 
associated (P = 0.000013) with increased expression of the UBR5 gene. It was therefore 
hypothesized that this allele might be favourable for strength and power-related sports. 
Indeed, our analysis demonstrated that the rs4734621 AA genotype was associated with 
high competition results in elite weightlifters (P = 0.016) and the A allele was over-
represented in elite strength athletes compared to controls (OR = 1.94, P = 0.04). The 
rs4734621 A allele was also over-represented in elite power (strength + explosive power) 
athletes compared to elite endurance athletes (OR = 2.2, P = 0.04). Next, given that the 
rs4734621 SNP was unavailable to be genotyped in the muscle fibre cohort given the 
different micro-array platformed used, we identified rs10505025 polymorphism in the UBR5 
gene was strongly linked (`D=1) with all 13 SNPs (described above) near the UBR5 gene, 
including rs473462. We found that the carriers of the rs10505025 AA genotype had 
significantly (P = 0.024) higher mean (SD) CSA of fast-twitch muscle fibres than carriers of 
the G allele: AA: 5796  1526 μm2; GA: 5260  1350 μm2; GG: 4011  983 μm2 (Figure 5B). 
Furthermore, the rs10505025 A allele was significantly over-represented in strength athletes 
(OR = 2.13, P = 0.05) and sprinters (OR = 2.93, P = 0.03) compared to endurance athletes. 
These genetic data support our primary findings that the UBR5 gene is associated with 
skeletal muscle hypertrophy and adaptation to strength/power/resistance training. Further, 
that variations affecting UBR5 gene expression are associated with cross-sectional area of 
fast-twitch muscle fibres while favouring strength / power versus endurance status in 
athletes. 
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Discussion 
 
UBR5 in atrophy and recovery from atrophy 
UBR5 is a HECT domain E3 ligase previously uncharacterised during and after skeletal 
muscle atrophy and recovery from atrophy. We demonstrate here that during atrophy evoked 
by tetrodotoxin (TTX) nerve silencing in rats, the UBR5 promoter was significantly 
hypomethylated and increased at the gene expression level early (3 days) in the time course 
of atrophy yet had returned to normal expression levels during later atrophy (14 days) where 
muscle mass loss was greatest. We have also previously demonstrated that the promoter 
regions of MuRF1 and MAFbx are hypomethylated during atrophy that corresponds with an 
increase in gene expression (Fisher et al., 2017), offering support for epigenetic alterations 
such as DNA methylation being inversely associated with gene expression of other E3 
ubiquitin ligases such as UBR5. Furthermore, in the present dataset we provide further 
support for the alternate roles of UBR5 in comparison with MuRF1 and MAFbx during 
muscle loss. After 7 days of continuous low frequency electrical stimulation (20Hz) (13% 
muscle mass loss), MuRF1 and MAFbx were significantly increased while no significant 
increases were observed in UBR5 expression. Comparable results were obtained after 3 
days of atrophy following nerve crush injury, whereby we observed significant increases in 
UBR5 gene expression that dropped back down at 7 days while MuRF1 and MAFbx 
remained elevated as muscle continued to waste at 7-14 days. Together, this data supports 
a potential role for UBR5 in early remodelling after a wasting stimulus such as disuse or 
nerve silencing rather than in the extensive atrophy of muscle per se.  
 
Because of its potential role in remodelling, we also looked to characterise UBR5 changes 
during recovery from atrophy as muscle mass returned towards pre-atrophy levels. Indeed, 
we demonstrated that after 7 days of recovery from TTX induced-atrophy, muscle mass was 
restored by approximately 52% and UBR5 was significantly hypomethylated and on average 
gene expression was upregulated while the other E3 ligases, MuRF1 and MAFbx were 
downregulated. While UBR5 gene expression just failed to reach significance (P = 0.1), this 
was again interesting given the alternate regulation of UBR5 vs. MuRF1 and MAFbx gene 
expression. Furthermore, these data support other published observations where 
MuRF1/MAFbx have been shown not be unchanged in adult rats during recovery from 
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atrophy induced by hindlimb unloading (Baehr et al., 2016). In the TTX model we only 
observed a partial 52% recovery of TA muscle mass over 7 days, yet saw a significant 
hypomethylation and average increase in UBR5 gene expression during recovery that might 
precede any later changes in protein abundance of UBR5. We therefore, measured UBR5 
protein levels at later time points post recovery (14 d). Furthermore, due to limited sample 
from TTX atrophy recovery experiments for analysis of protein (as well as the muscle only 
being partially recovered 50% at 7 days upon termination of the experiments)  we measured 
protein abundance after atrophy and recovery from hindlimb unloading in rats in new 
analysis of already published samples, specifically in the medial gastrocnemius muscle that 
was fully recovered (Baehr et al., 2014). Firstly, we identified that protein levels increased at 
3 days following HU but returned to baseline by 14 days where most atrophy occurred, 
mirroring the temporal regulation observed at the gene expression level in the TTX atrophy 
model. This suggested that the HU model at the protein level presented a similar response 
to nerve silencing TTX-atrophy at the gene expression level. Importantly, after 3- and 14-
days recovery from HU, we also observed a linear increase in UBR5 protein abundance, 
with the largest (approx. 50%) increase observed at 14 days where muscle mass was fully 
recovered. Additionally, there was a more rapid increase in aged muscle during recovery 
from atrophy at 3 days peaking at an approx. 70% increase at 7 and 14 days during 
recovery, with these aged animals previously showing impaired recovery vs. young adult rats 
(Baehr et al., 2014). This suggests that an increase in protein abundance is important during 
full recovery in healthy young adults, but even a large and robust increase in UBR5 does not 
enable a full recovery of muscle mass in aged muscle. Finally, after recovery from nerve 
crush injury in mice, the protein abundance of UBR5 also increased significantly by 50% 
(similar increase after recovery from HU) and peaked at 28 and 45 days relating to a full 
recovery of muscle mass after 60 days. Overall, taken together across TTX atrophy, nerve 
crush and HU models, these data suggest that UBR5 is elevated in response to early 
atrophy and recovery and supports a role for this gene and protein in remodelling in adult 
and aged skeletal muscle tissue.  
 
Despite these interesting findings, it is worth mentioning that while UBR5 protein abundance 
significantly increased at 28 and 45 days following recovery from nerve crush in mice, 
opposed to the TTX model, UBR5 gene expression did not change. While the reason for no 
change in mRNA versus increased protein abundance during recovery in the nerve crush 
model is not clear, it is worth mentioning that we analysed the gastrocnemius muscles 
because they recovered more over the time course versus the TA (data not shown). 
Whereas in the TTX model, UBR5 gene expression analysis was in the TA only (given the 
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delivery of the TTX only silences TA and EDL, not gastrocnemius) and the TA is known to 
have a higher proportion of fast fibres. This discrepancy between gene expression and 
protein levels following nerve crush in the gastrocnemius versus the other models, leads us 
to speculate that there are perhaps some important functions for UBR5 at the protein level 
across different fibre types. However, this requires further empirical evidence to support this 
hypothesis, where future experiments should look to perform western blotting or 
immunohistochemistry for UBR5 across muscles that contain different fibre type proportions. 
Indeed, a similar observation of no increase in gene expression but increases at the protein 
level occurred during human muscle cell differentiation. Previous studies have suggested 
UBR5 translocates into the nucleus in a complex that can silence transcription, for example 
in gene TRAF3 (Cho et al., 2017). However, UBR5 has also been shown to ubiquitinylate 
Groucho/TLE’s that are repressors of transcription and thus subsequently activate 
transcription of Armadillo/β-catenin (Flack et al., 2017). Furthermore, there is evidence that 
UBR5 can regulate translational machinery via interaction with CDK9 (Cojocaru et al., 2011) 
and PAIP2 (Yoshida et al., 2006). Therefore, this suggests that UBR5 localisation at the 
protein level, what it is binding to, what it ubiquitinates and its stability/ turnover would be an 
important avenue of future research in skeletal muscle atrophy and recovery from atrophy. 
This would be especially prudent in the nerve crush model, given the discrepancy in mRNA 
and protein data described above. Overall however, the atrophy and recovery data across 
models combined suggests that UBR5 is elevated early in atrophy and is reduced during 
later atrophy. Further, UBR5 is elevated during recovery whereas MuRF1/MAFbx are 
downregulated. More work needs to determine the post-transcriptional regulation of UBR5, 
its localisation, substrates and binding complexes to further understand its mechanistic role 
in these processes.  
 
UBR5’s role in skeletal muscle anabolism and hypertrophy 
Given, UBR5’s elevations during early remodelling during atrophy and the subsequent 
recovery we also aimed to characterise its role in anabolism and hypertrophy. Indeed, the 
data in this manuscript suggests for the first time that increases in gene expression of the 
HECT domain E3 ligase, UBR5, occurred following acute loading of mouse bioengineered 
muscle in-vitro and after hypertrophy following chronic intermittent electrical stimulation in 
rats in-vivo. The increase in UBR5 gene expression after acute loading also occurred in the 
other E3 ligases, MuRF1 and MAFbx, however, after chronic-stimulation induced 
hypertrophy MuRF1 and MAFbx did not increase whereas UBR5 increased. Together with 
the data above during atrophy and recovery, this data further supports that, at the gene 
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expression level, UBR5 is alternately regulated versus MuRF1/MAFbx after hypertrophy, but 
interestingly after acute anabolic loading UBR5, MuRF1 and MAFbx all demonstrate an 
increase. This is perhaps not surprising given that MuRF1 and MAFbx/Atrogin-1 have also 
been shown to increase acutely after eccentric contractions in humans (Yang et al., 2006; 
Louis et al., 2007). Furthermore, the increase in UBR5 gene expression after loading in 
bioengineered muscle (1.58 fold) supports our previous work in humans, demonstrating a 
similar fold change in UBR5 gene expression (1.71 fold) after a single bout of resistance 
exercise in humans (Seaborne et al., 2018b). While gene expression was significantly 
elevated, the present study identified only 1 out of 6 CpG sites located in UBR5 promoter to 
be hypomethylated after acute loading in bioengineered muscle, however this was not 
significant. This supported our previous studies where there was no change in UBR5 DNA 
methylation after acute resistance exercise in humans (Seaborne et al., 2018b). Despite this, 
significant hypomethylation of UBR5 has been demonstrated to occur after repeated/chronic 
training and retraining induced hypertrophy in humans (Seaborne et al., 2018b) and in the 
present study hypertrophy (14% increase in mass) in rat muscle after chronic intermittent 
electrical simulation evoked mean reductions in promoter UBR5 methylation 
(hypomethylation). However, in contrast with the aforementioned human study, the changes 
did not reach statistical significance. Currently, the data points towards repeated and chronic 
loading/exercise stimuli being required to cause promoter UBR5 hypomethylation, yet gene 
expression of UBR5 is elevated in response to both acute and chronic exercise stimuli. Also, 
given our previous work suggesting that hypomethylation of UBR5 is retained during 
detraining after a period of training induced atrophy, it is possible that once hypomethylation 
occurs it is relatively stable, and these changes can be retained over longer periods even 
when hypertrophic stimuli are removed. This hypothesis requires further investigation to be 
confirmed. 
 
In addition to significantly increased gene expression after acute anabolic and chronic 
hypertrophic stimuli in the present study, we also demonstrate that UBR5 protein abundance 
increased during human muscle cell differentiation and after hypertrophy in-vivo following 
synergist ablation (functional overload/FO) in mice. Indeed, during FO at first there was a 
significant decrease in UBR5 at 1 d, followed by a rapid and large increase at 3, 7 and 14 
days corresponding with extensive hypertrophy of 65% increase in muscle mass by 14 days. 
It is worth noting that while the initial significant reduction in UBR5 protein at 1d was initially 
surprising, in the same experiments and samples in earlier published studies at the gene 
expression level, MuRF1 and MAFbx mRNA were oppositely regulated (elevated) (Baehr et 
al., 2014), however were then downregulated at 3,7 and 14 days. This again suggesting that 
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MuRF/MAFbx have alternate regulation compared to UBR5, as our other data confirms 
above across the different models of atrophy, recovery and hypertrophy. Overall, this is the 
first study to associate increases in protein abundance of UBR5 with differentiation and 
hypertrophy in skeletal muscle. Future studies should look to overexpress UBR5 in 
differentiating skeletal muscle cells and also in tissue in-vivo to confirm its role in 
hypertrophy. Furthermore, because UBR5 is an E3 ligase, with apparently alternate 
regulation to the more extensively studied MuRF1 and MAFbx at the expression level, future 
studies should look to investigate its protein substrates. For example, studies in cancer cells 
have suggested that UBR5 can destabilise tumour suppressors such as MDM2/p53 by 
ubiquitination of upstream ribosomal protein L23 (RPL23), as well as tumour suppressor 
ECRG4, and its overexpression therefore enables growth and a reduction of apoptosis in 
colorectal cancer cells (Wang et al., 2017; Watanabe et al., 2018). Therefore, these 
interactions warrant further investigation in models of skeletal muscle anabolism and 
hypertrophy. Other studies also suggest that UBR5’s protein activity is important, due to 
phosphorylation by p90RSK (Cho et al., 2017) and MAPK1 (ERK2) in cells in response to 
epidermal growth factor (EGF) (Eblen et al., 2003), where ERK is a well-established 
regulator of muscle cell proliferation (Foulstone et al., 2004) and load-induced hypertrophy 
(Miyazaki et al., 2011) and p90RSK for protein synthesis in skeletal muscle tissue (Moore et 
al., 2011). Furthermore, in cancer, overexpression of UBR5 promotes tumour growth via 
destabilisation of PTEN (an inhibitor of PI3K/Akt) therefore allowing signalling via PI3K/AKT 
(Zhang et al., 2019), where PTEN and PI3K/Akt are key regulators of both muscle cell 
differentiation (Foulstone et al., 2004; Sharples et al., 2013) and muscle protein synthesis 
(reviewed in (Wackerhage et al., 2019)). Finally, UBR5 has been shown to destabilize p21 
(Ji et al., 2017), where low p21 is associated with maintenance of muscle during periods of 
atrophy and high levels of p21 associated with atrophy itself (Bongers et al., 2015). 
Therefore, UBR5 signalling (ERK, PTEN/PI3K/Akt/p90RSK), its targets (RPL23/p53, 
ECRG4, p21) and cellular location/transcription factor binding (Groucho/TLE’s, TRAF3) will 
be key future avenues of research to uncover its mechanistic role in muscle cell 
differentiation and muscle hypertrophy.  
Finally, we investigated genetic variations of the UBR5 gene that were associated with 
UBR5 gene expression in humans using the online tool GTEx (Battle et al., 2017) to further 
corroborate the animal in vivo data, human in vitro data and previous in vivo human data 
(Seaborne et al., 2018b). Subsequently, the genetic variants that were identified were found 
significant in various human and athlete cohorts including physically active men, 
strength/power or endurance trained athletes. Indeed, we identified 2 SNPs, the first 
rs4734621 AA genotype (associated with increased UBR5 gene expression) was related to 
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high competition results in elite weightlifters and the rs4734621 A allele was over-
represented in both elite strength athletes versus controls and elite power athletes versus 
endurance athletes. Further, the A allele of the rs10505025 polymorphism (which is strongly 
linked with rs4734621) was associated with greater CSA of fast-twitch muscle fibres in 
physically active men and was significantly over-represented in strength athletes and 
sprinters compared to endurance athletes. These genetic data support the animal data 
suggesting that where an increase in gene expression of UBR5 is expected that this is 
associated with hypertrophy. Furthermore, that adaptation to strength/resistance exercise 
and muscle size of fast fibres is associated with the aforementioned UBR5 polymorphisms in 
humans. The only study to date to investigate other E3 ligases polymorphisms and human 
muscle are studies in MuRF1 (rs2275950) that describe the AA homozygotes were stronger 
and demonstrate less muscle soreness in response to eccentric muscle damage compared 
with GG homozygotes (Baumert et al., 2018). At present no other studies have identified 
UBR5 polymorphisms to be associated with skeletal muscle size and performance in 
humans. 
 
Conclusion 
Using multiple models of skeletal muscle atrophy/injury, recovery from atrophy, anabolism 
and hypertrophy in-vivo and in-vitro, we demonstrate for the first time that the E3 ubiquitin 
ligase UBR5, in alternate fashion to MuRF1/MAFbx at the gene expression level, is elevated 
during recovery, anabolism and hypertrophy in animals in-vivo as well as human muscle cell 
regeneration in-vitro. Finally, in humans the A alleles of the rs10505025 and rs4734621 
SNPs that affect the expression of the UBR5 gene are strongly associated with larger fast-
twitch muscle fibres and strength/power performance. 
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Figure Legends 
 
Figure 1: A: Reductions in muscle weight after 7 days of continuous low frequency (20Hz) 
electrical stimulation. TA weight was expressed relative to whole animal body mass to 
normalize for interindividual differences in animal size (n = 6). Then expressed as 
percentage change from the untreated contralateral control limb for each animal. B: UBR5 
RNAi and negative control (neg con) plasmid injected into the TA muscle of C57/BL6 
male mice (n = 5) after 7 days post electroporation. Western blots using UBR5 antibody 
(monoclonal, D6087; Cell Signalling Technology) demonstrate a significant reduction (p 
value depicted on figure) in UBR5 protein, validating the antibody for use in skeletal muscle. 
Figure 2. A: UBR5 DNA methylation and gene expression during Tetrodotoxin (TTX) 
atrophy and recovery in rat tibialis anterior (TA) (n = 6 for 3/7/14 days (d); n = 4 for 
recovery). Significant (*) increases in gene expression of UBR5 at 3 and 7 d. Significant (*) 
hypomethylation of the UBR5 promoter at 3 and 14 d of TTX and after 7 days recovery. B: 
No change in UBR5 gene expression compared with significant increases in MuRF1 (*) and 
MAFbx (**) after 13% muscle mass atrophy as a result of ‘overtraining’ induced by 
continuous low frequency (20Hz) electrical stimulation (CLFS) (n = 3). C: UBR5 gene 
expression in comparison with MuRF1 and MAFbx taken from previously published data in 
the same conditions/samples (Fisher et al., 2017) during TTX atrophy and recovery from 
atrophy (n = 6 for 3/ 7 / 14 d, n = 4 for recovery). All genes significantly increased early 
during atrophy at 3 (*) & 7 () days, but with larger absolute fold changes in MuRF1/MAFbx 
vs. UBR5. During recovery MuRF1 and MAFbx were downregulated (MuRF1, p = 0.08 vs. 
14 D) whereas UBR5 was upregulated (p = 0.1 vs. control). D & E: Protein abundance of 
UBR5 during hindlimb unloading (HU) induced atrophy and reloading/recovery (/REL) in the 
medial gastrocnemius muscle of adult (D) and aged (E) rats (n = 6/group). UBR5 was 
increased early after 3 d atrophy without significance. UBR5 then returned to baseline after 
14 days of HU. Then in both adult (D) and aged (E) muscle UBR5 rapidly increased during 
recovery/REL resulting in significance (*) at 14 days in adult rats (p = 0.057), and both 7 and 
14 days in aged rats (*). All graphs are means  SEM. Significance at the level of p  0.05 
unless otherwise stated.  
Figure 3. A: Muscle weight (mg) of the gastrocnemius complex muscles (GSTC) in mice 
after nerve crush injury (NCI) over a period of atrophy (3 -14 days/d) and recovery (14 d - 60 
d) of muscle mass. The mice demonstrated a significant reduction in muscle weight of the 
GSTC at 7, 14, 21 and 28 d (all p  0.05 *) culminating in the largest average reduction of 
 This article is protected by copyright. All rights reserved. 41 
38% in muscle weight at 14 days post nerve crush injury after which point the muscle fully 
recovered between 45 - 60 days (31 - 46 days after maximal atrophy) demonstrated by no 
significant changes vs. baseline controls at 45 and 60 days (both p  0.05). B, C, D: UBR5 
(B), MuRF1 (C) and MAFbx (D) significantly ( p  0.001) increased at the gene expression 
level after 3 d post nerve crush injury and gene expression significantly (# p  0.001) 
decreased at 21, 28, 45- and 60-d post nerve crush injury. UBR5 returned towards baseline 
at 7 days whereas MuRF1 and MAFbx remained elevated at this timepoint post nerve crush 
injury (both p = 0.01  vs. UBR5 at 7 days, depicted on figure C & D). E: UBR5 protein 
abundance significantly increased early at 3 days post nerve crush injury, then returned to 
towards baseline after 7 and 14 d of atrophy and early during recovery at 21 d, before 
significantly increasing at 28 and 45 d during recovery ( p  0.001). All graphs are means  
SEM. N = 5-6/group. 
Figure 4. A: UBR5 gene expression and DNA methylation redrawn using original data (from 
(Seaborne et al., 2018b) after an initial period of resistance exercise induced hypertrophy 
(loading), followed by exercise cessation (unloading) where muscle mass returned to 
baseline levels, and a later period of resistance exercise induced hypertrophy (reloading). 
Bi: Top image is a representative macroscopic image of c2c12 bioengineered skeletal 
muscle used as a model to assess UBR5’s response to acute loading. Middle image is a 
representative microscopic image (middle) of C2C12 bioengineered skeletal muscle used as a 
model to assess UBR5’s response to acute loading. Middle image is a representative 
microscopic image (Nikon, Eclipse Ti-S, 10  magnification, scale bar = 50 μm) of C2C12 
bioengineered muscle stained with Phalloidin (actin- green) and DAPI (nuclei, blue) 
demonstrating highly aligned myotubes in the direction of uniaxial tension. Bottom image is 
the bioengineered muscle constructs loaded within the bioreactor chamber(s) as described 
in (Turner et al., 2019a). Bii: Significant increase in UBR5 gene expression at 30 minutes 
post-acute loading in bioengineered muscle in-vitro (n = 6 loaded / n = 6 unloaded controls), 
showing similar fold change increase as human tissue after 30 minutes of acute resistance 
exercise (RE) in-vivo in our previous studies (Seaborne et al., 2018b). Ci & Cii: UBR5 gene 
expression significantly increased after a 14% increase in muscle mass as a result of 4 
weeks of intermittent high frequency electrical stimulation in rats (n = 4), where UBR5 also 
demonstrated average reductions in DNA methylation albeit non-significantly (Ci). The 
increase in UBR5 gene expression in this model of hypertrophy occurred without increases 
in MuRF1 and MAFbx (Cii). D: UBR5 protein abundance significantly reduced in the 
plantaris muscle in mice after synergist ablation/functional overload (FO) at 1 day (p = 0.02), 
yet rapidly and significantly increased at 3, 7, and 14 days post FO (all p = 0.001) (n = 
3/group). Ei Representative images of morphological differentiation of human muscle 
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derived cells in monolayer cultures (n = 3) (scale bar 200 μm), that demonstrated increasing 
differentiation and myotube formation across the time-course. Eii: Myogenic regulatory 
factors (Myf5, MyoD, Myogenin) and MYHC (I & II) gene expression during human muscle 
cell differentiation identified an average increase in MyoD, Myogenin and MYHC I & II and 
reductions in Myf5 as cells differentiated into myotubes at 72 hrs and 7 days. UBR5 gene 
expression did not increase during differentiation. Eiii: UBR5 however demonstrated 
significant increases in protein levels at 72 hrs and 7 days of differentiation. All graphs are 
means  SEM. Significance at the level of p  0.05 unless otherwise stated in the figure.  
Figure 5: A: Example of a slow and fast serial section used for fiber size quantification from 
human participants. B: Box plot demonstrating that there was an increased frequency of 
large fast fibers within the human population that possessed the AA allele of the UBR5 
rs10505025 polymorphism. 
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Table 1. Gene expression primers. 
 
Species Gene Primer Sequence (5’-3’) Amplicon 
length (bp) 
Mouse 
 
 
 
3D 
Loading 
 
 
Nerve 
Crush 
 
 
Rat 
 
 
 
 
Ubr5 
 
Pol2rb 
 
MuRF1 
 
MAFbx 
 
MuRF1 
  
MAFbx 
 
Ubr5 
 
MuRF1 
 
F: GTCTGCTGGAGCTCGTGATT 
R: TGCTGGAATAACTGGCTGGG 
F: GGTCAGAAGGGAACTTGTGGTAT 
R: GCATCATTAAATGGAGTAGCGTC 
F: GAGGGCCATTGACTTTGGGA 
R: TTTACCCTCTGTGGTCACGC 
F: TCGACTGCCATCCTGGATTC 
R: TTCTTTTGGGCGATGCCACT 
F: GCTGGTGGAAAACATCATTGACAT 
R: CATCGGGTGGCTGCCTTT 
F: CTTTCAACAGACTGGACTTCTCGA 
R: CAGCTCCAACAGCCTTACTACGT 
F: GCACCAATCCTGACGACTCT 
R: AATGTGTTCTGCTCCGGTCC 
F: CCAAGCTTGTGGAAACAGCC 
R: CAATGCTCTTGATGAGCGGC 
106 
 
197 
 
96 
 
104 
 
76 
 
77 
 
83 
 
90 
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Human 
MAFbx 
 
Pol2ra 
 
UBR5 
 
Myf5 
 
MyoD 
 
Myogenin 
 
MYHC1 
 
MYHC2 
 
RPL13A 
 
 
F: CTTCTCGACTGCCATCCTGG 
R: GTTCTTTTGGGCGATGCCAC 
F: GCTGGACCTACTGGCATGTT 
R: ACCATAGGCTGGAGTTGCAC 
F: AGGCAACACCTTAGGAAGCC 
R: GCTCCAGCTGATGACCTAC 
F: TCAGCAGGATGGACGTGATG 
R: ACTCGTCCCCAAATTCACCC 
F: GCCACAACGGACGACTTCTA 
R: GTGCTCTTCGGGTTTCAGGA 
F: TCCCAGATGAAACCATGCCC 
R: AGGCCCCTGCTACAGAAGTA 
F: ATCTCTACGCCAGGGTCCTT 
R: GGCCATCTCAGAGTCGGAAC 
F: CAAAGGGACCATCCAGAGCA 
R: AGGGTTCATGGGGAAGACCT 
F: GGCTAAACAGGTACTGCTGGG 
R: AGGAAAGCCAGGTACTTCAACTT 
 
109 
 
102 
 
81 
 
102 
 
117 
 
103 
 
73 
 
103 
 
105 
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Table 2. Description of targeted DNA methylation assays for loci specific pyrosequencing analysis of UBR5 in Rat and Mouse samples. The 
CpG loci location for the rat assay is based on Ensembl Gene ID (ENSRNOG00000006816), Ensembl transcript ID (ENSRNOT00000009115) 
and Rnor_6.0/rn6 genomic build. For the mouse assay it is based on Ensembl Gene ID (ENSMUSG00000037487), Ensembl transcript ID 
(ENSMUST00000226414) and GRCm38/mm10 genomic build. 
 
Species CpG ID Location Position 
from TSS 
Chromatin 
Location 
Genomic 
Target 
Sequence 
Bisulfite 
converted 
Target 
Sequence 
Pyrosequencing 
Dispensation 
order 
 
Rat 
 
 
 All CpG 
 
Intron 1 
 
-126 to -
160 
 
Chr7: 76853715-
76853681 
 
 
AAGTCTTC
GTCACAGT
ACGCCTTG
GAATGAAT
GGCTCTAC
ACGTCT  
 
 
AAGTTTTY
GTTATAG
TAYGTTTT
GGAATGA
ATGGTTTT
ATAYGTTT 
 
GATGTTCGTCA
CTAGTGATCGT
TGATGATGCTC
TACTGATCGT  
 
 CpG-2  126 Chr7: 76853715   
 CpG-3  136 Chr13: 76853705   
 CpG-4  160 Chr13: 76853681   
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Mouse 
 
All CpG 
 
Intron 1 
 
+72 to 
+131 
 
Chr15:38078354-
38078295 
 
GGCGGGG
GAGGGGCA
CCTCCCTC
CTTTTTCCC
CTCCCCCA
CGGCCGCG
CCGGGGG
CCCTACCG
CCCCCTGT
AGG  
 
 
GGYGGG
GGAGGG
GTATTTTT
TTTTTTTT
TTTTTTTT
TTTAYGG
TYGYGTY
GGGGGTT
TTATYGTT
TTTTGTAG
G 
 
TGTCGGAGGCT
ACTCTCTGATCA
GTCAGTCAGTC
GGCTTGATCG  
 
 CpG-6  72 Chr15:38078354   
 CpG-7  110 Chr15:38078316   
 CpG-8  114 Chr15:38078312   
 CpG-9  116 Chr15:38078310   
 CpG-10  119 Chr15:38078307   
 CpG-11  131 Chr15:38078295   
 
 
